The Shanghai Intellectual Property Administration receives a warm praise from Roche Pharma China. [WeChat account: Shanghai _IPA]

The Shanghai Intellectual Property Administration or SIPA – based in East China's Shanghai – received a warm praise from Roche Pharma China on Sept 27, for its efficient and professional administrative adjudication of patent infringement disputes.

The intellectual property, or IP body defended the rights and interest of Roche Pharma China and stopped infringements within four months from the filing date of a landmark case involving the group, whose parent company is a famous international corporation based in Switzerland.

"SIPA overcame difficulties amid the COVID-19 pandemic and made an administrative decision in a timely fashion, which has safeguarded the legitimate rights of a multinational company and also heightened the company's confidence in Shanghai's innovation and business environment," said Long Weili, vice-president of corporate affairs and communications at Roche Pharma China.

The Roche case was one of the most successful cases for SIPA's administrative adjudication of patent infringement IP disputes.

Since handling the first case in 2019, the administration has focused on bio-medical patents and helped 10 leading international pharma companies to solve patent infringement disputes, with nobody pursuing administrative proceedings.

The Shanghai Intellectual Property Administration, as one of the first pilot units for the demonstration development of patent infringement administrative adjudication, has been dedicated to the protection of bio-medical patents.

It's also been dedicated to safeguarding the legitimate rights and interests of domestic and foreign innovation companies. The aim is to build a highland for bio-medical patent infringement administrative protection, as well as to support Shanghai's construction of an international intellectual property rights, or IPR protection highland and an IPR center, according to Yu Chen, deputy director of SIPA.